/
/
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
É necessária uma assinatura da JoVE para visualizar este conteúdo. Faça login ou comece sua avaliação gratuita.
Capítulos
- 00:05Título
- 00:30Determining Initial Gefitnib Concentration Using the 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenylterazolium Bromide (MTT) Assay
- 02:15Continuous Stepwise Dose-escalation of Gefitnib Treatment of PC-9 Cells
- 03:31Determine Initial Concentration of PHA665752 Using the MTT Assay
- 06:37Results: Two-step Dose-escalation Procedure to Establish Dual Resistance to EGFT-TKI and MET-TKI
- 08:21Conclusion
An in vitro method for establishing dual resistance to an EGFR-TKI and a MET-TKI in cancer cells is described. This method is useful for developing treatments for patients with EGFR-mutations, who exhibit disease progression despite EGFR-TKI treatment with MET-amplification. It can also be modified for inhibitors targeting other molecules.
